GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.